Binex Co Ltd
KOSDAQ:053030
Binex Co Ltd
Revenue
Binex Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
Binex Co Ltd
KOSDAQ:053030
|
Revenue
â‚©130.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
![]() |
Yuhan Corp
KRX:000100
|
Revenue
â‚©2.1T
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
![]() |
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Revenue
â‚©547.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
![]() |
Hanmi Pharm Co Ltd
KRX:128940
|
Revenue
â‚©1.5T
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Revenue
â‚©210.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Revenue
â‚©437.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
Binex Co Ltd
Glance View
BINEX Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Busan, Busan. The company went IPO on 2001-08-07. The Company’s products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. The company also manufactures bio medicines and raw materials. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Binex Co Ltd's Revenue?
Revenue
130.1B
KRW
Based on the financial report for Dec 31, 2024, Binex Co Ltd's Revenue amounts to 130.1B KRW.
What is Binex Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was -16%. The average annual Revenue growth rates for Binex Co Ltd have been -1% over the past three years , 1% over the past five years , and 8% over the past ten years .